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Brain-derived neurotrophic factor (BDNF) plays a critical role in neurodevelopment and neuroplasticity.
Altered BDNF signaling is thought to contribute to the pathogenesis of schizophrenia (SZ) especially in
relation to cognitive deﬁcits. Clozapine (CLZ) has been shownabeneﬁcial effect on cognition in SZ in some
studies and a detrimental effect in others. To examine serum BDNF, two groups of chronically medicated
DSM-IV SZ patients (n=44), on treatment with clozapine (n=31) and typical antipsychotics (n=13) had





CLZ daily dose (r=0.394, p=0.028), but not with typical antipsychotic daily dose (r=0.208, p=0.496).
This study suggests that serum BDNF levels are correlated with CLZ daily dose, and this may lead to the
cognitive enhancement as seen in patients with SZ under CLZ. Despite the strong evidence that chronic
administration of CLZ is effective for patients with SZ, it is still unknown whether atypical antipsychotic
drugs regulate BDNF expression. Serum BDNF levels concentration in SZ merits further investigations
with regard to the role of neurotrophins in the cognitive response to treatment with CLZ and other
atypical antipsychotics.
chizophrenia (SZ) is a complex and severe brain disorder with
oorly deﬁned etiology and pathophysiology [27]. Cognitive func-
ion may be markedly impaired in patients with SZ [20]. Several
euroimaging and postmortem ﬁndings, along with the behavioral
nd cognitive deterioration observed in schizophrenic patients,
ould reﬂect a signiﬁcant neurodegenerative process [19]. Gen-
ral cognitive ability assessed either by formal cognitive tests or by
sing educational achievement as a proxymeasure, is lower in chil-
ren at risk to develop SZ compared to their healthy counterparts
27].
Brain-derived neurotrophic factor (BDNF) is the most widely
istributed neurotrophin in the central nervous system, important
or neurogenesis, neuronal survival, and normalmaturation of neu-
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ral developmental pathways [25]. Eventually in the adult, it is not
only important for synaptic plasticity and dendritic growth, but
also essential to long-term memory [3,25]. Altered BDNF-signaling
is thought to contribute to the pathogenesis of SZ, especially in
relation to cognitive deﬁcits [5,9] and it is suggested that genetic
variation in the BDNF gene modulates prefrontral and limbic
functioning [2]. Nevertheless, analysis of serum BDNF as a poten-
tial biomarker in this disease has provided controversial data
[5].
Serum BDNF levels in patients with SZ have been widely
reported in literature, some ﬁndings of decreased [16,24,33] and
others of increased BDNF serum levels [10] compared to controls.
A recent meta-analysis with SZ patients reported an association
between reduced BDNF and age, but not between BDNF and med-
Open access under the Elsevier OA license.ication dosage [15]. Studies with drug naïve patients identiﬁed
decreased BDNF at the onset of psychosis [18,23] and indicated that
low serum BDNF levels at the onset of SZ is associated with a long
durationof untreatedpsychosis [28]. Itwas also reported that BDNF
levels at the onset of SZ may be associated with the pathophysio-
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Table 1
Characteristics of patients with schizophrenia (SZ) under clozapine or typical antipsychotic.
SZ clozapine (n=31) SZ typical (n=13) p-Value
Gender (male/female) 24/7 11/2 0.703*
Age (years)a 42.7 (10.0) 39.5 (8.3) 0.283**
IMC (kg/m2)a 27.3 (4.6) 29.4 (5.2) 0.268**
Years of illnessb 20.0(17.0) 12.0(17.5) 0.268***
BDNF (pg/g)a 0.14 (0.08) 0.14 (0.08) 0.957**
BPRS scoreb 10.5 (13.0) 16.0 (13.5) 0.791***
Antipsychotic daily dose, in mg of chlorpromazine equivalentsa 553.2 (192.8) 472.8 (268.8) 0.269**
BPRS, Brief Psychiatry Rating Scale.











































and atypical antipsychotics may differently affect blood and brain
BDNF levels in SZ and that atypical antipsychotics may favorably




ogical processes as well as the severity of positive and negative
sychotic symptoms [29].
The introduction of clozapine (CLZ), an atypical antipsychotic,
or the treatment of poorly responsive patientswith SZ has fostered
idespread hope among patients, their families, and caregivers
14]. Importantly, CLZ has been shown a beneﬁcial effect on cogni-
ion in SZ in some studies and a detrimental effect in others [26].
Given theevidenceof thepharmacological role of antipsychotics
n BDNF levels, and its correlation to cognition, we assessed serum
DNF levels in chronically stable schizophrenic patients in order to
stablish a relationship with CLZ daily doses.
This study protocol was approved by the Ethical Committee
f the Hospital de Clínicas de Porto Alegre, RS, Brazil (HCPA).
n accordance with the Declaration of Helsinki, all subjects were
dvised about the procedure and signed the informed consent form
rior to participation in the study. Forty-four outpatients from
he HCPA Schizophrenia Program were enrolled to this study pro-
ocol. They all were on chronic medication, thirty-one subjects
aking CLZ, and thirteen, typical antipsychotics. Patients receiv-
ng typical antipsychotics were all treated with haloperidol and
ome with adjunctive chlorpromazine to it. Medications doses are
resented in mg of chlorpromazine equivalents to facilitate com-
arisons between them.
Noneof themhad anyneurological disease, brain tumor, thyroid
isease, severe hepatic disease, severe cardiac disease or any other
sychiatric diagnosis. This groupof patients had to fulﬁll Diagnostic
ndStatisticalManual ofMentalDisorders; fourthEdition (DSM-IV)
6] criteria for SZ and their psychopathological state was measured
ith 18-itemBrief Psychiatry Rating Scale (BPRS) [30]. Each subject
ad 5ml blood samples collected by venipuncture without antico-
gulants, and serum was obtained by centrifugation at 300× g for
min and kept frozen at −70 ◦C for up to 6 months, until the assay.
BDNF levels were measured with ELISA, using a commercial kit
ccording to the manufacturer’s instructions (Chemicon, USA) as
escribed elsewhere [10].
Analysis was performed using Statistical Product and Service
olutions 16.0 Version (SPSS). Demographic and clinical character-
stics were analyzed using Chi-Square, Mann–Whitney or T-test.
escriptive analyses are presented asmean (standard deviation) or
edian (interquartile range) and p-values <0.05 were considered
igniﬁcant. Relationships between variables were assessed with
earson rank correlation coefﬁcient.
The subjects’ characteristics are summarized in Table 1. Serum
DNF levels were signiﬁcantly correlated with CLZ daily dose
r=0.394, p=0.028; Fig. 1), but not with typical antipsychotic daily
ose (r=0.208, p=0.496), both in mg of chlorpromazine equiva-
ents.
Our study showed that serum BDNF levels are directly associ-
ted with CLZ daily dose in schizophrenic patients. Higher BDNF
evelswere found in patientswith higher antipsychotic daily doses,which are in line with both the property of atypical antipsychotics
to increase BDNF, and the literature demonstrating higher BDNF
levels in chronically medicated SZ patients [10].
In line with our ﬁndings, previous studies have reported that
serum BDNF levels were positively correlated with CLZ dose
[16,32]. It was also found that chronic treatment with the atypi-
cal antipsychotics CLZ and olanzapine increase BDNF expression in
the rat hippocampus while haloperidol decreases BDNF expression
[1]. Xiu et al. [36] reported a signiﬁcant difference in BDNF levels
between antipsychotic types: risperidone was found to produce a
more robust effect on BDNF compared to CLZ and typical antipsy-
chotic. However, some studies could not conclude that treatment
with antipsychotics alters serum BDNF levels in patients with SZ
[15,24,33]. Such differences between typical and some atypical
drugs regarding neurotrophic and neuroprotective mechanisms
could have implications on the clinical course of the disorder and
on brain loss associated with SZ [11–13,15,16].
Despite some inconsistency, these ﬁndings seem to corrobo-
rate the hypothesis of a positive relationship between the dose of
the antipsychotic medication CLZ and serum BDNF level. Further-
more, it has already been reported that different effects of typicalFig. 1. Positive correlation between serum brain-derived neurotrophic factor
(BDNF) and antipsychotic daily dose in mg of chlorpromazine equivalents in 31
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Cognitivedeﬁcits are increasingly seenaspartof thecorepathol-
gy of SZ and two areas with well-documented roles in multiple
omains of cognition, hippocampus and the prefrontal cortex, are
oted to have reductions in BDNF mRNA expression and BDNF
rotein post-mortem [18,21]. A post-mortem study reported a
eduction in BDNF production and availability in the dorsolateral
refrontal cortex of patients with SZ and suggested that intrinsic
ortical neurons, afferent neurons, and target neurons may receive
ess trophic support in this disorder [35].
In animal experiments, the acquisition and maintenance of
patial memory are impaired when BDNF signaling is decreased.
owever, brain BDNF is increased when rodents perform a spatial
earning taskorarehoused incognitively stimulatingenvironments
34]. A recent study suggested that serum BDNF levels might serve
saperipheral biomarker for theeffectsof intensive cognitive train-
ng [34]. Concerning behavioral intervention, it has been found that
DNF levels were signiﬁcantly higher in patients on a hypocaloric
iet [17]. Nevertheless, there are no empirical methods to identify
ny speciﬁc features in patients with SZ, in particular, to determine
heir cognitive status [4]. These ﬁndings seem to corroborate that
DNF is related to cognition, and since CLZ increases serum BDNF
evels, as found by us and others [16,32], we could hypothesize
hat schizophrenic patients treated with CLZ may have a cognitive
nhancement.
These data also support the growing body of evidence regarding
he modulating effect of CLZ on cognition. There are some reports
hat CLZ may produced symptomatic and cognitive improvements
psychomotor speed, verbal ﬂuency, verbal learning and mem-
ry), positive changes that appeared to occur independently of one
nother and may reﬂect an impact on remediable brain function-
ng and may offer an advantage to patients with schizophrenia
y enhancing the possibility of better vocational functioning and
uality of life [20,21,31]. Zhao et al. [37] reported that CLZ might
mprove negative symptoms and improve cognitive dysfunction,
lthough it could not improve hypofrontality – reduced cerebral
lood ﬂow in the prefrontal lobe. Molina et al. [22] found that CLZ
ay normalize the pattern of brain activation during an atten-
ion test (Stroop) to a higher degree than risperidone in patients
esistant to the latter. A recent trial indicated that memantine
djunctive to CLZ, but not any other antipsychotic, signiﬁcantly
mproved positive, negative and cognitive symptoms in treatment
efractory patients with SZ [7]. However, the symptomatological
mprovement is not related to BNDF serum levels [8] driving to
ther pathways of cognitive improvement than neurotrophins.
Our report must be interpreted in light of its limitations. Firstly,
control group was not included. Secondly, this study failed to
nclude clinical parameters of cognition. Nevertheless, this is the
rst report detailing the relationship between BDNF level and CLZ
aily dose. For cognitive improvement approaching by CLZ admin-
stration, a cross-sectional design is limited. However, the present
esults gave us the compelling evidence for a follow-up study of
lozapine use, serumBDNF levels and cognitive improvements that
as been planned by our group. Finally, despite the fact that we
ound a statistically signiﬁcant correlation (p=0.028) between the
DNF andCLZdaily dose, the value of such correlation is quite small
r=0.394) and explains only around 16% of the variance accounted
or by such association.
This study suggests that serum BDNF levels are correlated with
LZ daily dose, and this may lead to the cognitive enhancement as
een in patients with SZ under CLZ. Despite the strong evidence
hat chronic administration of CLZ is effective for patients with SZ,
t is still unknown whether atypical antipsychotic drugs regulate
DNF expression. Serum BDNF levels concentration in SZ merits
urther investigations with regard to the role of neurotrophins in
he cognitive response to treatment with CLZ and other atypical
ntipsychotics.
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